Dr. Brinton will present results from “Allopregnanolone Regenerative Therapeutic for Parkinson’s Disease: Open-Label Clinical Trial Preliminary Imaging Outcomes” at the 2025 AD/PD Conference in Vienna, Austria. This pilot study examined the effects of the naturally occurring neurosteroid allopregnanolone on brain tissue volume, dopamine transporters, and other brain health parameters in patients with Parkinson’s Disease using imaging. The clinical status and quality of life of these patients were also evaluated. ADMdx collaborated with Dr. Brinton’s team to provide analyses of DaTscan images which measure dopamine transporters that are reduced with Parkinson’s Disease, and provided CorInsights MRI reports that quantify regional brain volumes. This exploratory trial showed positive effects upon patients in multiple measures. Dr. Brinton, lead investigator of the study, is the Director of the UA Center for Innovation in Brain Science and Professor of Pharmacology at the University of Arizona Health Sciences.